Expression of erbB receptors mRNA in thyroid tissues

Kato, S

doi:10.1016/s0304-4165(04)00112-6

Cited by 4 publications

(4 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…354 Increases in ERBB3 along with EGFR and ERBB2 were also reported for papillary carcinoma of thyroid. 355,356 Involvement of ERBB3 in oral cancer was confirmed in a rat model, where Erbb3 protein was increased in carcinogen-induced oral carcinomas. 357 In diabetic rats, this protein was increased in hyperplastic and dysplastic lesions also.…”

Section: Melanomasmentioning

confidence: 88%

The ERBB3 receptor in cancer and cancer gene therapy

2008

View full text Add to dashboard Cite

ERBB3, a member of the epidermal growth factor receptor (EGFR) family, is unique in that its tyrosine kinase domain is functionally defective. It is activated by neuregulins, by other ERBB and nonERBB receptors as well as by other kinases, and by novel mechanisms. Downstream it interacts prominently with the phosphoinositol 3-kinase/AKT survival/mitogenic pathway, but also with GRB, SHC, SRC, ABL, rasGAP, SYK and the transcription regulator EBP1. There are likely important but poorly understood roles for nuclear localization and for secreted isoforms. Studies of ERBB3 expression in primary cancers and of its mechanistic contributions in cultured cells have implicated it, with varying degrees of certainty, with causation or sustenance of cancers of the breast, ovary, prostate, certain brain cells, retina, melanocytes, colon, pancreas, stomach, oral cavity and lung. Recent results link high ERBB3 activity with escape from therapy targeting other ERBBs in lung and breast cancers. Thus a wide and centrally important role for ERBB3 in cancer is becoming increasingly apparent. Several approaches for targeting ERBB3 in cancers have been tested or proposed. Small inhibitory RNA (siRNA) to ERBB3 or AKT is showing promise as a therapeutic approach to treatment of lung adenocarcinoma.

show abstract

Section: Melanomasmentioning

confidence: 88%

The ERBB3 receptor in cancer and cancer gene therapy

2008

View full text Add to dashboard Cite

show abstract

“…Multiple ligands bind EGFR, ERBB3 or ERBB4, inducing rapid receptor dimerization, with a marked preference for ERBB2 as dimerization partner. EGFR and ERBB2 are often found in thyroid cancers (Kato et al, 2004). EGF stimulates the growth of human thyroid carcinoma cells and rat FRTL-5 cells in vitro.…”

Section: Tyrosine Kinase Receptorsmentioning

confidence: 99%

Molecular Biology of Thyroid Cancer

Viglietto¹,

Marco²

2011

Contemporary Aspects of Endocrinology

View full text Add to dashboard Cite

“…The sequences of the primers for ErbB2, ErbB3, and ErbB4 have been published previously. 41 The amplification was performed with negative and positive controls using the optimal number of cycles to ensure that the amplification was completed within the exponential range. Thus, PCR amplifications for ErbB2, ErbB3, ErbB4 and b-actin were performed with 32, 40, 40 and 25 cycles, respectively.…”

Section: Subjectsmentioning

confidence: 99%

Neuregulin1-induced cell migration is impaired in schizophrenia: association with neuregulin1 and catechol-o-methyltransferase gene polymorphisms

Sei

Ren-Patterson

et al. 2007

Mol Psychiatry

View full text Add to dashboard Cite

Neuregulin1 (NRG1), a candidate susceptibility gene for schizophrenia, plays a critical role in neuronal migration and central nervous system development. However, its relation to schizophrenia pathogenesis is unknown. Here we show that B lymphoblasts migrate to NRG1 through the ErbB-signaling system as observed in neuronal cells. We assessed NRG1-induced cell migration in B lymphoblasts from patients with schizophrenia and found that NRG1-induced migration is significantly decreased compared with control individuals in two independent cohorts. This impaired migration is related at least in part to reduced AKT phosphorylation in the patients. Moreover, the magnitude of NRG1-induced migration is associated with polymorphisms of the NRG1 and catechol-o-methyltransferase genes and with an epistatic interaction of these genes. This study demonstrates that the migratory response of schizophrenia-derived cells to NRG1 is impaired and is associated with genetic variations in more than one schizophrenia susceptibility gene, providing a novel insight into potential neurodevelopmental mechanisms of schizophrenia.

show abstract

Expression of erbB receptors mRNA in thyroid tissues

Cited by 4 publications

References 0 publications

The ERBB3 receptor in cancer and cancer gene therapy

The ERBB3 receptor in cancer and cancer gene therapy

Molecular Biology of Thyroid Cancer

Neuregulin1-induced cell migration is impaired in schizophrenia: association with neuregulin1 and catechol-o-methyltransferase gene polymorphisms

Contact Info

Product

Resources

About